ATTITUDES ON WARFARIN PHARMACOGENETIC TESTING IN CHINESE PATIENTS AND PUBLIC

被引:4
|
作者
Chan, Sze Ling [1 ]
Low, Joshua Jun Wen [2 ]
Chia, Kee Seng [1 ,3 ,4 ,5 ,6 ]
Wee, Hwee-Lin [2 ,7 ]
机构
[1] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore
[2] Natl Univ Singapore, Dept Pharm, Singapore 117548, Singapore
[3] Natl Univ Singapore, Ctr Mol Epidemiol, Singapore 117548, Singapore
[4] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[5] Genome Inst Singapore, Singapore, Singapore
[6] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117595, Singapore
[7] Singapore Gen Hosp, Dept Rheumatol & Immunol, Singapore, Singapore
关键词
Warfarin; Pharmacogenetic testing; Attitudes; Asian; ADVERSE DRUG-REACTIONS;
D O I
10.1017/S026646231300069X
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: Genetic factors affecting warfarin maintenance dose have been well established, but patient acceptance is a necessary consideration for the successful clinical implementation of warfarin pharmacogenetic testing (WPGT). In this study, we aimed to determine the attitudes toward WPGT among Singaporean Chinese. Methods: A total of 194 warfarin patients and 187 members of the public completed a structured survey on paper and the Internet, respectively. Attitudes were expressed as willingness to undergo WPGT (single item with 5-point response) and expectations and concerns about WPGT (two multi-item scales). Relationships between attitudes and socio-demographic and clinical variables were explored using Fisher's exact test, Student's t-test, one-way analysis of variance or Pearson's correlation. Results: Majority of respondents were willing to or neutral about undergoing WPGT. Both patients and public had relatively high expectations (mean [SD]: 3.77 [0.63], and 3.97 [0.55], respectively) and moderately high concerns (mean [SD]: 3.30 [0.69] and 3.33 [0.68], respectively) about WPGT. Willingness to undergo WPGT was associated with gender, educational status, length of warfarin treatment, and number of chronic diseases among warfarin patients, and with history of adverse drug reactions and number of chronic diseases among the public. Higher expectation of WPGT was associated with higher willingness (p < .001 in both populations), while higher concern was associated with lower willingness to undergo WPGT among the public (p = .004) but not among patients (p = .072). Conclusion: Patient acceptance is not a major barrier to clinical implementation of WPGT but patient education is necessary and the ethical, social, and legal issues should be addressed.
引用
收藏
页码:113 / 120
页数:8
相关论文
共 50 条
  • [31] Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients
    Bazan, Naglaa Samir
    Sabry, Nirmeen Ahmed
    Rizk, Amal
    Mokhtar, Sherif
    Badary, Osama
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2012, 34 (06) : 837 - 844
  • [32] Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients
    Naglaa Samir Bazan
    Nirmeen Ahmed Sabry
    Amal Rizk
    Sherif Mokhtar
    Osama Badary
    International Journal of Clinical Pharmacy, 2012, 34 : 837 - 844
  • [33] Evaluation of Pharmacogenetic Algorithm for Warfarin Dose Requirements in Japanese Patients
    Takeuchi, Fumihiko
    Kashida, Mitsuo
    Okazaki, Osamu
    Tanaka, Yuriko
    Fukuda, Shoji
    Kashima, Toshitaka
    Hosaka, Shigeru
    Hiroe, Michiaki
    Kimura, Sosuke
    Kato, Norihiro
    CIRCULATION JOURNAL, 2010, 74 (05) : 977 - 982
  • [34] Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing?
    Scott, Stuart A.
    Lubitz, Steven A.
    PHARMACOGENOMICS, 2014, 15 (06) : 719 - 722
  • [35] Establishment of a Han Chinese-specific pharmacogenetic-guided warfarin dosing algorithm
    Pei, Lin
    Tian, Xiaoyi
    Long, Yan
    Nan, Wenhui
    Jia, Mei
    Qiao, Rui
    Zhang, Jie
    MEDICINE, 2018, 97 (36)
  • [36] Exploring perceptions, knowledge, and attitudes regarding pharmacogenetic testing in the medically underserved
    Gawronski, Brian E.
    Cicali, Emily J.
    McDonough, Caitrin W.
    Cottler, Linda B.
    Duarte, Julio D.
    FRONTIERS IN GENETICS, 2023, 13
  • [37] Public Perspectives About Pharmacogenetic Testing and Managing Ancillary Findings
    Haga, Susanne B.
    Tindall, Genevieve
    O'Daniel, Julianne M.
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2012, 16 (03) : 193 - 197
  • [38] Systematic Review of Pharmacogenetic Warfarin Dosing
    van Schie, Rianne M. F.
    Jorgensen, Andrea L.
    de Boer, Anthonius
    Maitland-van der Zee, Anke-Hilse
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2009, 24 (10) : 1171 - 1171
  • [39] Pharmacogenetic determinants of warfarin in the Indian population
    Naushad, Shaik Mohammad
    Kutala, Vijay Kumar
    Hussain, Tajamul
    Alrokayan, Salman A.
    PHARMACOLOGICAL REPORTS, 2021, 73 (05) : 1396 - 1404
  • [40] Understanding the pharmacogenetic approach to warfarin dosing
    Glurich, Ingrid
    Burmester, James K.
    Caldwell, Michael D.
    HEART FAILURE REVIEWS, 2010, 15 (03) : 239 - 248